Company

Overview:
Meracle brings relief and assurance to patients with respiratory and chronic ailments by optimizing the delivery of
therapy in a safe, reliable and efficient manner, with the ultimate goal of setting the industry's benchmarks and
standards. We endeavor to continue to improve on our unique solution of a user-friendly and convenient digital
platform for both patients and doctors to collaborate seamlessly and efficiently, focusing on enhancing the patient's
well being. The team brings together over 50 years of experience in medical device development and
commercialization. Driven by our personal experience of family diagnosed with asthma, we understand the
frustration of frequent exacerbation and emergency room visits despite regular follow-ups and increasing medication
dosage. Thus, the inspiration emerged to bring this innovation to patients and address respiratory diseases.

Pain:
Asthma is a huge and growing global problem. More than 300 million people have asthma and this number will rise to
400 million in 5 years. While asthma cannot be cured, it can be controlled with treatment and management.
However, it continues to take a heavy toll on patients despite the development of many new treatments, due to
incorrect administration technique of medication and poor compliance. More than half of patients inhale their
medication wrongly causing drugs to be deposited at the back of the throat instead of the lungs. This results in
diminishing efficacy and unwanted side effects when medication is swallowed instead. To make matters worse 50-
78% do not take their medication regularly. Because of this, up to 7 in 10 patients still have poor asthma control
causing exacerbation of symptoms such as shortness of breath and resulting in twice the number of hospitalization

Solution:
We developed the Whizz, a simple, intuitive and convenient solution to improve the management of asthma by
increasing the efficiency of medication delivered into the lungs while tracking intake data to augment the assessment
of treatment outcomes. Through trials we have shown that the Whizz improves technique and compliance by 100%,
leading to better asthma control and reduced symptoms. This is a solution that benefits multiple stakeholders, by first
improving the quality of life of patients and helping them gain a sense of control over their situation. Doctors have
access to objective data that makes it easier to target accurate prescription medication and governments are able to
improve public health and reduce the burden on an overwhelmed healthcare system.

Company information: Technology:
Meracle Pte Ltd The Whizz spacer provides immediate and actionable feedback to users

that intuitively reinforce correct inhalation technique with each breath.
410 Jurong West St 42 #02- Inhalation indicators turn green showing optimal inhalation is achieved,
893 Singapore 640410 ensuring medication is delivered deep into the lungs. Red indicators show
+6594237107 that inhalation is suboptimal, prompting users to self correct in the next
Website inhalation, as patients are usually instructed to breath in 6-8 times for
https://www.meraclehealth.com/ each actuation of the inhaler through a spacer. The spacer is paired to a
Email mobile application that makes compliance easy, trackable and fun. It
Rachel@meraclehealth.com provides daily alerts to simplify the treatment regimen, and has a
rewards function that allows caregivers to set goals to motivate children
Year Founded: 2018 to take their medication accurately and consistently. Furthermore, this
# of Employees: 3 information is shared with doctors, providing them with objective data to
conveniently track progress and adjust treatment more effectively. This
Funding: data can also be used to customize therapy, detect patterns and predict
Total raised to date: NIL risk and is valuable to hospitals, insurance and pharmaceutical
companies.
We have been awarded

competitive (non-dilutive)
IP/Defensibility:
grants from the Singapore PCT application PCT/SG2020/050217. Titled: Inhalable medical aerosol
government amounting to dispensing system, covering novel aspects of the hardware and software.
SG$1.5mil to support the Freedom to operate report showed market clearance with no risk of
development of the Whizz. infringement.



Total Seeking: US$360,000 Competition/Competitive Advantage:
Use of funds: Regulatory The Whizz is the only solution in the market that addresses technique
and compliance at the same time. Regular spacers do not offer any
testing; including feedback with minimal innovation over the past 20 years. Connected or
biocompatibility (ISO10993), smart inhalers are a recent development and helps to monitor
electrical testing (IEC60601) compliance but tracking is a non sequitur if medication is not delivered
and regulatory submission correctly in the first place.
Financials:
Revenue: NIL Market Size/Target Customers:
Burn Rate: NIL (Founders are There are 339mil people with asthma and 251mil people with Chronic
Obstructive Pulmonary disease (COPD) globally. The global spacer market
bootstrapping) alone is valued at US$1.33 billion. Market drivers are urbanization as well
Cash Flow Positive in: 2023 as the increasing prevalence of chronic respiratory conditions with
patients recovering from COVID-19. Our initial target customers are
Highlights: children and the elderly with respiratory conditions who are most
• IoT Tribe Cohort vulnerable to inhaler error and compliance, but will extend it to the
adults too because everyone deserves effective inhaled medication.
• Top 100 Global startups

at Slingshot 2019
Business Model:
Team: The Whizz spacer will be sold to patients with a small subscription fee on
Co-Founder: Victor Loh the mobile app. We also sell the replacement chambers separately, to be
• Founding partner, former replaced every 6 months. We are working with medical device
MD of Vicplas International distributors and pharmaceutical companies to facilitate market access.
Ltd & Forefront Medical
Technology Pte Ltd Milestones:
• Listed 3 companies in the • Conducted usability and clinical trials, showing that the Whizz
Singapore stock exchange improved asthma control and reduced symptoms
Co-Founder: Melvin Loh • Completed manufacturability and ready to scale with manufacturing
• Lead & managed the partners in place
• Prepared design history file for regulatory submission
innovation of novel medical
• Ready for product launch after completing regulatory tests and
devices within NUS
obtaining approval
(National University of
• Engaged regional distributors and pharmaceutical companies to
Singapore) with 11 facilitate market access
successfully

commercialized products
Exit:
• Operational experience in We anticipate listing the company via an Initial Public offering (IPO) in
setting up medical device 2023. We have started preliminary discussions with Deloitte Singapore.
manufacturing plants in
China and Singapore

Co-Founder: Rachel Hong
• Lead product engineering
teams at NUS through
design and development of
a portfolio of 21 projects
• Designed and invented
novel medical devices of
various applications
including vascular and
gastrointestinal implants